Skip to main content
. 2023 Mar 31;7:84–89. doi: 10.5414/ALX02390E

Figure 2. A: Antibody responses to SARS-CoV-2 vaccine (WIBP-CorV, Sinopharm) in patients with allergic rhinitis receiving an allergen-specific immunotherapy, modified from Yao et al. [12]. B: TFH2 response to SARS-CoV-2 vaccine in patients with allergic rhinitis receiving allergen immunotherapy, modified from Yao et al. [12].

Figure 2